WallStreetZenWallStreetZen

NASDAQ: VVOS
Vivos Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for VVOS

Based on 1 analyst offering 12 month price targets for Vivos Therapeutics Inc

Min Forecast
$3.10+2,619.3%
Avg Forecast
$3.10+2,619.3%
Max Forecast
$3.10+2,619.3%

Should I buy or sell VVOS stock?

Based on 1 analyst offering ratings for Vivos Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their VVOS stock forecasts and price targets.

VVOS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-04

1 of 1

Forecast return on equity

Is VVOS forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is VVOS forecast to generate an efficient return on assets?

Company
-69.98%
Industry
10.13%
VVOS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VVOS earnings per share forecast

What is VVOS's earnings per share in the next 2 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$1.37
Avg 2 year Forecast
-$0.84

VVOS revenue forecast

What is VVOS's revenue in the next 2 years based on estimates from 6 analysts?

Avg 1 year Forecast
$22.8M+9.27%
Avg 2 year Forecast
$34.8M+66.35%
VVOS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VVOS revenue growth forecast

How is VVOS forecast to perform vs Medical Devices companies and vs the US market?

Company
9.27%
Industry
5.59%
Market
19.89%
VVOS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VVOS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VVOS vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
VVOS$0.11$3.10+2,619.30%Buy
CODX$0.37N/AN/A
NUWE$5.68N/AN/A
ICCM$0.87$30.00+3,348.28%Strong Buy
XAIR$2.24$10.00+346.43%Strong Buy
View Top Medical Device Stocks

Vivos Therapeutics Stock Forecast FAQ

Is Vivos Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: VVOS) stock is to Buy VVOS stock.

Out of 1 analyst, 0 (0%) are recommending VVOS as a Strong Buy, 1 (100%) are recommending VVOS as a Buy, 0 (0%) are recommending VVOS as a Hold, 0 (0%) are recommending VVOS as a Sell, and 0 (0%) are recommending VVOS as a Strong Sell.

If you're new to stock investing, here's how to buy Vivos Therapeutics stock.

What is VVOS's earnings growth forecast for 2026-2027?

(NASDAQ: VVOS) Vivos Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 53.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,326.68%.

Vivos Therapeutics's earnings in 2026 is -$25,457,000.On average, 6 Wall Street analysts forecast VVOS's earnings for 2026 to be -$27,549,621, with the lowest VVOS earnings forecast at -$42,191,518, and the highest VVOS earnings forecast at -$15,842,943.

In 2027, VVOS is forecast to generate -$16,895,116 in earnings, with the lowest earnings forecast at -$42,782,988 and the highest earnings forecast at -$2,112,392.

What is VVOS's revenue growth forecast for 2026-2027?

(NASDAQ: VVOS) Vivos Therapeutics's forecast annual revenue growth rate of 9.27% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 5.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 19.89%.

Vivos Therapeutics's revenue in 2026 is $20,901,000.On average, 6 Wall Street analysts forecast VVOS's revenue for 2026 to be $459,475,527, with the lowest VVOS revenue forecast at $411,071,564, and the highest VVOS revenue forecast at $547,652,822.

In 2027, VVOS is forecast to generate $699,483,542 in revenue, with the lowest revenue forecast at $483,033,732 and the highest revenue forecast at $952,165,911.

What is VVOS's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: VVOS) forecast ROA is -69.98%, which is lower than the forecast US Medical Devices industry average of 10.13%.

What is VVOS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year VVOS price target, the average VVOS price target is $3.10, with the highest VVOS stock price forecast at $3.10 and the lowest VVOS stock price forecast at $3.10.

The Wall Street analyst predicted that Vivos Therapeutics's share price could reach $3.10 by Jun 4, 2027. The average Vivos Therapeutics stock price prediction forecasts a potential upside of 2,619.3% from the current VVOS share price of $0.11.

What is VVOS's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: VVOS) Vivos Therapeutics's current Earnings Per Share (EPS) is -$1.90. On average, analysts forecast that VVOS's EPS will be -$1.37 for 2026, with the lowest EPS forecast at -$2.10, and the highest EPS forecast at -$0.79. In 2027, VVOS's EPS is forecast to hit -$0.84 (min: -$2.13, max: -$0.11).

What is VVOS's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: VVOS) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.